


=>

Uploading C:\Program Files\Stnexp\Queries\10-566,040a.str



chain nodes :

10 11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

chain bonds :

10-11 11-12 12-13 12-14 13-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

5-7 6-9 7-8 8-9 12-13 12-14 13-15

exact bonds :

10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 11:14:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 151 TO ITERATE

100.0% PROCESSED 151 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2283 TO 3757

PROJECTED ANSWERS: 3 TO 163

L6 3 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 11:14:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2662 TO ITERATE

100.0% PROCESSED 2662 ITERATIONS

37 ANSWERS

SEARCH TIME: 00.00.01

L7 37 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST	178.82	384.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.20

FILE 'CAPLUS' ENTERED AT 11:15:09 ON 08 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2008 VOL 148 ISS 19
FILE LAST UPDATED: 7 May 2008 (20080507/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l7

L8 4 L7

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:120732 CAPLUS <<LOGINID:20080508>>
DOCUMENT NUMBER: 142:219278
TITLE: Preparation of indazolylacrylamides as SGK-1 inhibitors
INVENTOR(S): Drewry, David Harold; Linn, James Andrew; Veal, James Marvin
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
WO 2005011681	A1	20050210	WO 2004-US23680	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1648448 A1 20060426 EP 2004-778961 20040723

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007500700 T 20070118 JP 2006-521933 20040723


US 20080058515 A1 20080306 US 2006-566040 20060126

PRIORITY APPLN. INFO.: US 2003-490828P P 20030729

WO 2004-US23680 W 20040723

OTHER SOURCE(S): CASREACT 142:219278; MARPAT 142:219278

GI



AB The title compds. I [D = CR and X = N, or D = N and X = CR, or D and X = CR (wherein R = H, halo, CN, alkyl); R1 = (Q)m(Q1)n(Q2)p (wherein Q = arylene, heteroarylene; m = 0-1; Q1 = O(CH2)q, (CH2)rC(O), SO2; n = 0-1; q = 0-4; r = 1-4; Q2 = alkyl, cycloalkyl, OH, etc.; p = 0-1); R2 = H, alkyl; NR1R2 = (un)substituted heterocyclyl, heterocyclic spiro ring system; R3, R4 = H, alkyl; R5 = H, halo, CN, OH, etc.] which are useful in the treatment of diseases mediated by inappropriate SGK-1 activity, were prepared Thus, reacting acryloyl chloride with 1,3-benzothiazol-6-amine followed by reaction of the resulting crude intermediate with 3-iodoindazole afforded I [D, X = CH; R1 = 1,3-benzothiazol-6-yl; R2-R5 = H] which showed pIC50 of > 6.0 against SGK-1. The pharmaceutical composition comprising the compound I is disclosed.


IT 842132-03-0P 842132-04-1P 842132-05-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indazolylacrylamides as SGK-1 inhibitors)

RN 842132-03-0 CAPLUS

CN Benzoic acid, 4-[[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-04-1 CAPLUS

CN Benzoic acid, 4-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 842132-05-2 CAPLUS


CN Benzoic acid, 3-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-,
methyl ester (CA INDEX NAME)

Double bond geometry as shown.




IT 842131-72-0P 842131-74-2P 842131-76-4P
842131-77-5P 842131-78-6P 842131-80-0P
842131-81-1P 842131-82-2P 842131-83-3P
842131-84-4P 842131-85-5P 842131-86-6P
842131-87-7P 842131-88-8P 842131-89-9P
842131-90-2P 842131-91-3P 842131-92-4P
842131-93-5P 842132-06-3P 842132-07-4P
842132-08-5P 842132-09-6P 842132-10-9P
842132-11-0P 842132-12-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of indazolylacrylamides as SGK-1 inhibitors)
RN 842131-72-0 CAPLUS
CN 2-Propenamide, N-(2-benzothiazolyl-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX
NAME)

Double bond geometry as shown.




RN 842131-74-2 CAPLUS
CN 2-Propenamide, N-(2-cyanophenyl)-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX
NAME)

Double bond geometry as shown.



RN 842131-76-4 CAPLUS
CN 2-Propenamide, N-(3-chlorophenyl)-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX
NAME)


Double bond geometry as shown.



RN 842131-77-5 CAPLUS

CN 2-Propenamide, N-(2,3-dihydro-1H-inden-5-yl)-3-(1H-indazol-3-yl)-, (2E)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 842131-78-6 CAPLUS

CN 2-Propenamide, N-[4-(dimethylamino)phenyl]-3-(1H-indazol-3-yl)-, (2E)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 842131-80-0 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-5-quinolinyl-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-81-1 CAPLUS

CN 2-Propenamide, N-[3-(acetylamino)phenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-82-2 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-(3,4,5-trimethoxyphenyl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-83-3 CAPLUS

CN 2-Propenamide, N-(3-benzoylphenyl)-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-84-4 CAPLUS

CN 2-Propenamide, N-[3-chloro-4-(4-morpholinyl)phenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-85-5 CAPLUS

CN 2-Propenamide, N-[5-[(diethylamino)sulfonyl]-2-methoxyphenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-86-6 CAPLUS

CN 2-Propenamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-87-7 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-[3-methoxy-4-[2-[(2-phenoxyethyl)amino]ethoxy]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-88-8 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-89-9 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-[3-methoxy-4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-90-2 CAPLUS

CN 2-Propenamide, 3-(1H-indazol-3-yl)-N-[3-methoxy-4-[2-(methylpropylamino)ethoxy]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-91-3 CAPLUS

CN 2-Propenamide, N-[4-[2-[[2-(4-chlorophenyl)ethyl]amino]ethoxy]-3-methoxyphenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-92-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[4-[[2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-2-methoxyphenoxy]ethyl]amino]-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 842131-93-5 CAPLUS

CN 2-Propenamide, N-[4-[2-(4-acetyl-1-piperazinyl)ethoxy]-3-methoxyphenyl]-3-(1H-indazol-3-yl)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-06-3 CAPLUS

CN Benzoic acid, 3-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-
(CA INDEX NAME)


Double bond geometry as shown.



RN 842132-07-4 CAPLUS

CN Benzamide, 4-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-08-5 CAPLUS

CN Benzamide, 4-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-N-methyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-09-6 CAPLUS

CN Benzamide, 4-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-N-methyl-N-(1-methyl-3-pyrrolidinyl)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-10-9 CAPLUS

CN Benzamide, 3-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-11-0 CAPLUS

CN 2-Propenamide, 3-[(1H-indazol-3-yl)-N-[3-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 842132-12-1 CAPLUS

CN Benzamide, N-ethyl-3-[[(2E)-3-(1H-indazol-3-yl)-1-oxo-2-propen-1-yl]amino]-
N-(4-pyridinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



IT 842132-16-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of indazolylacrylamides as SGK-1 inhibitors)

RN 842132-16-5 CAPLUS

CN 2-Propenamide, N-[4-(2-bromoethoxy)-3-methoxyphenyl]-3-(1H-indazol-3-yl)-,
(2E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

3



THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:117027 CAPLUS <<LOGINID::20080508>>

DOCUMENT NUMBER: 132:166128
 TITLE: Preparation of substituted isoquinolines as anticonvulsants
 INVENTOR(S): Coulton, Steven; Harling, John David; Porter, Roderick Alan; Thompson, Mervyn
 PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007993	A1	20000217	WO 1999-EP5583	19990803
W: CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			GB 1998-16984	A 19980805
OTHER SOURCE(S):	MARPAT 132:166128			
GI				



AB The title compds. [I; Z = a carbocyclic or heterocyclic or a fused carbocyclic or heterocyclic ring containing at least one aromatic ring; X = CH, N; Y = H, alkyl, halo; P = CH:CH and Q = NR1, or P = CH:CH and Q = NR1CH2, or P = NH and Q = CR1a:CH; R1 = H, phenylalkyl, alkyl; R1a = H, halo, phenylalkyl, alkyl; R2 = H, halo, NO2, etc.; R3 = H, phenylalkyl, alkyl, etc.; R7-R12 = H, alkyl] including tetrahydroisoquinolinyl cinnamides and acrylamides which are indicated to be useful for the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid hemorrhage or neural

shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc. and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, etc., were prepared Thus, reacting (E)-7-(2-carboxyvinyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-Bu ester with aniline followed by treatment of the intermediate with trifluoroacetic acid afforded (E)-II which showed statistically significant increase (140%) in seizure threshold at 10 mg/kg p.o. in mice (MEST test).

IT 258514-53-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted isoquinolines as anticonvulsants)

RN 258514-53-3 CAPLUS

CN 2-Propenamide, 3-(2,3-dihydro-1H-indazol-3-yl)-N-(1,2,3,4-tetrahydro-2-methyl-7-isoquinoliny)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:233906 CAPLUS <<LOGINID:20080508>>

DOCUMENT NUMBER: 130:267434

TITLE: Preparation of 2-cyano-3-oxo-3-benz[glindazolepropanamides and analogs as kynurenine-3-hydroxylase inhibitors

INVENTOR(S): Pevarello, Paolo; Varasi, Mario; Amici, Raffaella; Toma, Salvatore; Speciale, Carmela

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.P.A., Italy

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
WO 9916753	A2	19990408	WO 1998-EP6051	19980923


WO 9916753 A3 19990520
 W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KE, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2302025 A1 19990408 CA 1998-2302025 19980923
 AU 9913343 A 19990423 AU 1999-13343 19980923
 EP 1019380 A2 20000719 EP 1998-956836 19980923
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 JP 2001518469 T 20011016 JP 2000-513839 19980923
 PRIORITY APPLN. INFO.: GB 1997-20899 A 19971001
 WO 1998-EP6051 W 19980923
 OTHER SOURCE(S): MARPAT 130:267434
 GI



AB Title compds. [I; R = COCH(CN)Z(CH2)mR2; R1 = H or 1-2 of halo, alkyl, alkoxy, etc.; R2 = alkyl, (un)substituted Ph, -heterocyclyl; Z = CONH, CO, SO2; Z1 = O or NR3; R3 = alkyl, CH2Ph, pyridyl, etc.; Z2 = N, NO, CH; m = 0-6] were prepared. Thus, α -tetralone was condensed with (CO2Et)2 and the product cyclocondensed with MeNHNH2 to give, after dehydrogenation, I (Z1 = MeN, Z2 = CH)(II; R = CO2Et) which was condensed with MeCN and the product condensed with PhNCO to give II [R = C(OH):CH(CN)CONHPh](III). Data for biol. activity of III Na salt were given.


IT 222293-75-6P 222293-78-9P 222293-82-5P
 222293-83-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-cyano-3-oxo-3-benz[glindazole]propanamides and analogs as kynurenine-3-hydroxylase inhibitors)

RN 222293-75-6 CAPLUS
 CN 2-Propenamide, 2-cyano-3-hydroxy-3-(1-methyl-1H-benz[glindazol-3-yl]-N-phenyl- (CA INDEX NAME)




RN 222293-78-9 CAPLUS

CN 2-Propenamide, 2-cyano-3-hydroxy-N-phenyl-3-(1-phenyl-1H-benz[gl]indazol-3-yl)- (CA INDEX NAME)



RN 222293-82-5 CAPLUS


CN 2-Propenamide, 2-cyano-3-hydroxy-3-(1-methyl-1H-benz[gl]indazol-3-yl)-N-phenyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 222293-83-6 CAPLUS


CN 2-Propenamide, 2-cyano-3-hydroxy-N-phenyl-3-(1-phenyl-1H-benz[gl]indazol-3-yl)-, monosodium salt (9CI) (CA INDEX NAME)




● Na

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:113653 CAPLUS <<LOGINID::20080508>>
 DOCUMENT NUMBER: 130:168365
 TITLE: Preparation of fused heterocyclic compounds as
 kynurenine-3-hydroxylase inhibitors
 INVENTOR(S): Pevarello, Paolo; Varasi, Mario; Heidempergher,
 Franco; Greco, Felicita; Speciale, Carmela
 PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906375	A1	19990211	WO 1998-EP4218	19980702
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2296606	A1	19990211	CA 1998-2296606	19980702
AU 9887317	A	19990222	AU 1998-87317	19980702
EP 1001941	A1	20000524	EP 1998-938689	19980702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001512107	T	20010821	JP 2000-505134	19980702
PRIORITY APPLN. INFO.:			GB 1997-16101	A 19970730
			WO 1998-EP4218	W 19980702
OTHER SOURCE(S):		MARPAT 130:168365		
GI				



I



II


AB The title compds. [I; a, b, c = all single bonds; or a, b, c = all double bonds; or a = double bond and b, c = single bonds; m = 0-6; W = CONH, SO₂, CO; X = O, S, NR₂ (wherein R₂ = H, C1-6 alkyl, PhCH₂, etc.); R, R₁ = H, halo, OH, etc.; Q = C1-14 alkyl, (un)substituted Ph ring or unsatd. pentat. heteromonocyclic ring containing two or three heteroatoms chosen independently from O, S and N], useful as kynurenine-3-hydroxylase inhibitors, were prepared and formulated. Thus, treatment of 2-cyano-3-(1-methyl-1H-indazol-3-yl)-3-oxo-N-phenylpropanamide (preparation given) with 0.1 N NaOH in EtOH afforded acrylamide II as sodium salt which showed IC₅₀ of 1.1 μM against KYN-3-OH.

IT 220487-67-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused heterocyclic compds. as kynurenine-3-hydroxylase inhibitors)

RN 220487-67-2 CAPLUS

CN 2-Propenamide, 2-cyano-3-hydroxy-3-(1-methyl-1H-indazol-3-yl)-N-phenyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	24.68	409.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-6.40

FILE 'REGISTRY' ENTERED AT 11:18:35 ON 08 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2008 HIGHEST RN 1019993-29-3
DICTIONARY FILE UPDATES: 7 MAY 2008 HIGHEST RN 1019993-29-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-566,040b.str



```

chain nodes :
10 11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
chain bonds :
7-10 10-11 11-12 12-13 12-14 13-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
5-7 6-9 7-8 7-10 8-9 10-11 11-12 12-13 12-14 13-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

```

G1:C,N

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom


```

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 19 sss sam

SAMPLE SEARCH INITIATED 11:19:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1563 TO ITERATE

100.0% PROCESSED 1563 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 28889 TO 33631

PROJECTED ANSWERS: 3009 TO 4671

L10 50 SEA SSS SAM L9

=>

Uploading C:\Program Files\Stnexp\Queries\10-566,040c.str



chain nodes :

10 11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

chain bonds :

10-11 11-12 12-13 12-14 13-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

5-7 6-9 7-8 8-9 12-13 12-14 13-15

exact bonds :

10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom


20:Atom 22:CLASS

L11 STRUCTURE UPLOADED

=> d l11

L11 HAS NO ANSWERS

L11 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l11 sss sam

SAMPLE SEARCH INITIATED 11:20:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 224 TO ITERATE

100.0% PROCESSED 224 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3583 TO 5377

PROJECTED ANSWERS: 3 TO 163

L12 3 SEA SSS SAM L11

=> s l11 sss full

FULL SEARCH INITIATED 11:21:09 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4234 TO ITERATE

100.0% PROCESSED 4234 ITERATIONS

38 ANSWERS

SEARCH TIME: 00.00.01

L13 38 SEA SSS FUL L11

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST	180.20	589.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

FILE 'CAPLUS' ENTERED AT 11:21:19 ON 08 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2008 VOL 148 ISS 19
FILE LAST UPDATED: 7 May 2008 (20080507/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l13

L14 8 L13

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L14 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:588231 CAPLUS <<LOGINID:20080508>>
DOCUMENT NUMBER: 141:140440
TITLE: Preparation of indazoles and their use as
anti-inflammatory, antirheumatic, and antiarthritic
agents
INVENTOR(S): Konno, Yasuo; Ono, Tomoyasu; Kitagawa, Kazuhiro;
Inoue, Shinichi; Tanaka, Katsuhisa; Yamada, Shozo;
Asao, Tetsuji
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 54 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
JP 2004203804	A	20040722	JP 2002-376012	20021226

PRIORITY APPLN. INFO.:


JP 2002-376012

20021226

OTHER SOURCE(S):

MARPAT 141:140440

GI



AB Title agents contain indazoles I [R1 = H, [(mono- or di-lower alkyl)amino-substituted] lower alkyl, acyl, lower alkoxy carbonyl, lower alkyl- or aryl-substituted SO2; R2 = H, lower alkyl(oxy); R3 = H, halo; R4 = H, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl, (un)substituted NH2, acyl, etc.; R5 = H, protecting group] or their pharmacol. acceptable salts as active ingredients. Thus, cyclocondensation of 5,6-diaminoindazole with PhCHO in AcNMe2 gave 90% I (R1-R3 = R5 = H, R4 = Ph), which at 300 mg/kg p.o. inhibited type II-collagen-induced arthritis by 96.7% in mice.

IT 724766-89-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolobenzimidazoles as anti-inflammatory, antirheumatic, and antiarthritic agents)

RN 724766-89-6 CAPLUS

CN 2-Propenamide, 3-(1,7-dihydroimidazo[4,5-f]indazol-6-yl)-N-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:299968 CAPLUS <<LOGINID:20080508>>


DOCUMENT NUMBER: 133:150502

TITLE: Synthesis and SAR of benzimidazole anthelmintics

AUTHOR(S): Gaur, N. M.; Patil, S. V.; Mourya, V. K.; Wagh, S. B.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, College of Pharmacy, Nashik, 420 002, India

SOURCE: Indian Journal of Heterocyclic Chemistry (2000), 9(3),
227-230
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Prof. R. S. Varma
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB β -Benzimidazolyl α -Me crotonic acid anilides I (X = H, 3-Cl, 4-Cl, 4-Me, 4-MeO), β -benzimidazolyl α -Me crotonic acid amides II (X = O, CH₂, NMe), β -benzimidazolyl Me butyramides III, and β -benzimidazolyl α -Me butyranilides IV were synthesized and tested for anthelmintic activity. It was found that the m-chloro derivative I (X = 3-Cl) showed maximum activity while p-methoxy derivative showed min. activity. A correlation of Hammett substituent constant and activity is given.


IT 286930-50-5P 286930-51-6P 286930-52-7P
286930-53-8P 286930-54-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, anthelmintic activity, structure-activity relationship, and Hammett substituent constant of benzimidazoles)

RN 286930-50-5 CAPLUS

CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-2-methyl-N-phenyl-, (2Z)- (CA

INDEX NAME)


Double bond geometry as shown.



RN 286930-51-6 CAPLUS

CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-N-(3-chlorophenyl)-2-methyl-, (2Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 286930-52-7 CAPLUS

CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-N-(4-chlorophenyl)-2-methyl-, (2Z)-
(CA INDEX NAME)


Double bond geometry as shown.



RN 286930-53-8 CAPLUS


CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-2-methyl-N-(4-methylphenyl)-, (2Z)-
(CA INDEX NAME)

Double bond geometry as shown.




RN 286930-54-9 CAPLUS
CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-N-(4-methoxyphenyl)-2-methyl-,
(2Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:467095 CAPLUS <<LOGINID:20080508>>
DOCUMENT NUMBER: 131:228686
TITLE: Synthesis and novel reactions of 2,3-dimethyl-1H-pyrrolo[1,2-a]-benzimidazol-1-one with secondary amines and N-bromosuccinimide
AUTHOR(S): Shetgiri, N. P.; Kokitkar, S. V.
CORPORATE SOURCE: Department of Chemistry, The Institute of Science, Mumbai, 400 032, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(3), 312-316
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:228686
GI



AB N,N-Disubstituted- β -(2-benzimidazolyl)- α,β -dimethylacrylamides I (R1 = H, Cl; R2 = morpholine, piperidine, etc.), 2-bromomethyl-3-methyl-1H-pyrrolo[1,2a]benzimidazol-1-one II (R1 = H; R2 = Br; X = O) and 2,3-dimethyl-1H-pyrrolo[1,2a]benzimidazole-1-thione II (R1 = R2 = H; X = S) have been synthesized from 2,3-dimethyl-1H-pyrrolo[1,2a]benzimidazol-1-one II (R1 = H, Cl; R2 = H; X = O). Compds. I have been synthesized via two different routes and screened for their antimicrobial and anthelmintic activities.


IT 243843-18-7P 243843-25-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of dimethylpyrrolobenzimidazolone and conversion to benzimidazolyl dimethylacrylamides, bromomethylpyrrolobenzimidazolone, and dimethylpyrrolobenzimidazolethione)


RN 243843-18-7 CAPLUS

CN 2-Butenamide, 3-(1H-benzimidazol-2-yl)-2-methyl-N,N-diphenyl- (CA INDEX NAME)



RN 243843-25-6 CAPLUS

CN 2-Butenamide, 3-(5-chloro-1H-benzimidazol-2-yl)-2-methyl-N,N-diphenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

10


THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:146669 CAPLUS <<LOGINID::20080508>>
 DOCUMENT NUMBER: 92:146669
 ORIGINAL REFERENCE NO.: 92:23837a,23840a
 TITLE: Synthesis of 3-(1-methyl-5-nitro-2-benzimidazolyl)acrylic acid derivatives as expected antischistosomal agents
 AUTHOR(S): Omar, Nabil M.; Farag, Hassan H.; Omar, Farghaly A.
 CORPORATE SOURCE: Fac. Pharm., Univ. Assiut, Assiut, Egypt
 SOURCE: Zeitschrift fuer Naturforschung, Teil B: Anorganische Chemie, Organische Chemie (1979), 34B(10), 1427-30
 CODEN: ZNBAD2; ISSN: 0340-5087
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 92:146669
 GI



AB Several ester and amide derivs. of 3-(1-methyl-5-nitro-2-benzimidazolyl)acrylic acid (I) prepared for testing as potential antischistosomal agents. I was prepared from 1-methyl-5-nitro-2-benzimidazolecarboxaldehyde and $\text{CH}_2(\text{CO}_2\text{H})_2$. N-Ethoxycarbonyl-2-ethoxydihydroquinoline was used as the coupling agent for the esterifications and amidations.
 IT 73237-63-5P 73237-64-6P 73282-60-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 73237-63-5 CAPLUS
 CN 2-Propenamide, N-(3-chlorophenyl)-3-(1-methyl-5-nitro-1H-benzimidazol-2-yl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 73237-64-6 CAPLUS

CN 2-Propenamide, 3-(1-methyl-5-nitro-1H-benzimidazol-2-yl)-N-(2-nitrophenyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 73282-60-7 CAPLUS

CN 2-Propenamide, 3-(1-methyl-5-nitro-1H-benzimidazol-2-yl)-N-phenyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L14 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:76369 CAPLUS <<LOGINID::20080508>>

DOCUMENT NUMBER: 74:76369

ORIGINAL REFERENCE NO.: 74:12395a,12398a

TITLE: Benzimidazole derivatives. XXV. Synthesis of 3-(1-methyl-2-benzimidazolyl)acrylic acid and its derivatives

AUTHOR(S): Popov, I. I.; Simonov, A. M.; Kolodyazhnaya, S. N.

CORPORATE SOURCE: Rostov-na-Donu Gos. Univ., Rostov-on-Don, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (11), 1566-8

CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB Treatment of I with Cl₃CCO over ZnCl₂ and then with NaOH afforded II (X = OH), which gave II (X = OR) with SOCl₂ followed by ROH (R = Me, Et). II (X = OR) were also prepared by oxidizing I with SeO₂, followed by treatment with Ph₃P:CHCO₂R. II (X = NHP, NET₂, piperidino) were prepared from II (X


= Cl·HCl) and the corresponding amines.

IT 30780-03-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 30780-03-1 CAPLUS

CN 2-Benzimidazoleacrylanilide, 1-methyl- (8CI) (CA INDEX NAME)



L14 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1969:512864 CAPLUS <<LOGINID::20080508>>

DOCUMENT NUMBER: 71:112864

ORIGINAL REFERENCE NO.: 71:21003a,21006a

TITLE: Fluorescent alkylating agents. 1-(β-chloroethyl)bisbenzimidazoles

AUTHOR(S): Tsou, Kwan Chung; Rabiger, Dorothy J.; Sobel, Barbara
CORPORATE SOURCE: Sch. of Med., Univ. of Pennsylvania, Philadelphia, PA, USA

SOURCE: Journal of Medicinal Chemistry (1969), 12(5), 818-22
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB cis- and trans-1-(β-Chloroethyl)bisbenzimidazoles (I) (R = H or Me, R1 = H or Me) have been synthesized as fluorescent alkylating agents. Preliminary in vivo study with HeLa cells shows that such compounds can be useful to demonstrate the intranuclear alkylation in dividing cells.

IT 24156-52-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 24156-52-3 CAPLUS

CN 2-Benzimidazoleacrylanilide, 2'-amino-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

L14 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1963:454940 CAPLUS <<LOGINID::20080508>>
DOCUMENT NUMBER: 59:54940
ORIGINAL REFERENCE NO.: 59:10024d-h
TITLE: Benzimidazole derivatives. XIII. Transformations of
2-formyl-1-methylbenzimidazole
AUTHOR(S): Dalgatov, D. D.; Simonov, A. M.
CORPORATE SOURCE: State Univ., Rostov-on-Don
SOURCE: Zhurnal Obshchei Khimii (1963), 33(3), 1007-10
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. CA 55, 16520f; 58, 13936f. Heating 1-methyl-2-hydroxymethylbenzimidazole in 2N H2SO4 in the presence of AgNO3 to 70° and treating the solution gradually with K2S2O8 gave after filtration and neutralization, followed by extraction with CHCl3, 1-methyl-2-formylbenzimidazole (I), m 110°; a more satisfactory preparation in 50% yield was secured by oxidation of 1,2-dimethylbenzimidazole with SeO2 at 95° in dry dioxane. Heating 2-hydroxymethylbenzimidazole with Leueotrope O in aqueous NaOH 2 hrs. gave after removal of PhNMe2 with steam 1-benzyl-2-hydroxymethylbenzimidazole, m. 186.5-7°. I and AcPh in the presence of 2% aqueous NaOH rapidly gave 83% 2-(2-benzoylvinyl)-1-methylbenzimidazole (II), m. 154-5°, which gave an orange solution in H2SO4 (2,4-dinitrophenylhydrazones m. 262°). This was brominated in CCl4 to γ-(1-methyl-2-benzimidazolyl)-β,γ-dibromopropiophenone, m. 134°. II and MeI in EtOH 2 hrs. gave II methiodide, m. 236°, which with aqueous KOH 1 hr. gave yellow N-β-benzoylacrylyl-N,N'-dimethyl-o-phenylenediamine, m. 156.5°. I and AcPh in EtOH treated gradually with 20% aqueous KOH, heated briefly at 100°, and kept 2 hrs. gave colorless 1-methyl-2-bis(phenacylethyl)benzimidazole (II), m. 184°. Similarly were prepared: yellow 2-(β-pbromobenzoylvinyl)-1-methylbenzimidazole, m. 159 60°, and colorless 1-methyl-2-bis(p-bromophenacylethyl)benzimidazole, m. 186.5-87°. I and cyclohexanone in MeOH in the presence of 10% KOH 0.5 hr. at reflux gave yellow 2-(1-methyl-2-benzimidazolylmethylene)cyclohexanone, m. 237°. I and 1,2-dimethylbenzimidazole-MeI in MeOH-piperidine 4 hrs. gave yellow 1,2-bis(1-methyl-2-benzimidazolyl)ethylene-MeI (III), decomposed 273°, which with aqueous alc. KOH 1 hr. gave yellow N-[β-(1-methyl-2-benzimidazolyl)acryloyl]-N,N'-dimethyl-o-phenylenediamine, m. 186°. 1,2-Dimethylbenzimidazole with excess EtI gave the monoethiodide, m. 188-90°. 1,2-bis(1-methyl-2-benzimidazolyl)ethene-EtI, yellow, m. 232-3°. IT 97078-58-5P, Acrylanilide, N-methyl-2'-(methylamino)-3-(1-methyl-2-benzimidazolyl-RL: PREP (Preparation)
(preparation of)
RN 97078-58-5 CAPLUS
CN 2-Benzimidazoleacrylanilide, N,1-dimethyl-2'-(methylamino)- (7CI) (CA INDEX NAME)



L14 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1923:19661 CAPLUS <<LOGINID::20080508>>

DOCUMENT NUMBER: 17:19661

ORIGINAL REFERENCE NO.: 17:3027b-i

TITLE: Action of o-phenylenediamine upon the anhydrides of

diphenylmaleic, homophthalic and diphenic acids

AUTHOR(S): Bistrzycki, A.; Fassler, Karl

SOURCE: Helvetica Chimica Acta (1923), 6, 519-35

CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.

AB Diphenylmaleic anhydride and o-C₆H₄(NH₂)₂ in boiling EtOH give an 85-905

yield of N-[2'-aminoanil]diphenylmaleic imide (diphenylmaleic-2''-

aminoanil), orange-yellow, decomp. 207-8°. In spite of the free

NH₂ group, it is insol. in HCl. Ac derivative, yellow, m. 224°.

Heated above its m. p., the imide loses H₂O, forming 85% of

[α,β-diphenylacrylenel]-2, 1-benzimidazole (I), brown, m.

186°. The concentrated H₂SO₄ solution is brownish red with a violet tinge.

I also results by heating the components but in very poor yields. I,

heated with KOH in EtOH and then acidified with AcOH, yields

β-[benzimidazolyl-2'']-α,β-diphenylacrylic acid (II),

contains 1 H₂O, gradually turns orange on heating and m. 186°

(decomposition). After standing several days in absolute EtOH, it contains 1

mol.

EtOH. Et ester, short needles, which yield I on heating. Anilide, m.

278° (decomposition). The condensation of o-C₆H₄(NH₂)₂ and homophthalic

anhydride in boiling EtOH yields 2-[carboxymethyl]-benz-[2'-aminoanilide],

o-HO₂CCCH₂C₆H₄CONHC₆H₄NH₂(?), turns yellow at 150° and then

gradually m. Ag salt, sensitive to light. o-Phenyleneacetyl-2,1-

benzimidazole (III), yellow, m. 345° (decomposition), results upon

heating the base at 200° for 10 min. It is not affected by MeONa

in MeOH, concentrated NH₄OH at 100 or 200°, PhNH₂ at 190° or

boiling PhNH₂-Diphenic anhydride and o-C₆H₄(NH₂)₂ give a 71% yield of

diphen-2''-aminoanilidecarboxylic acid, o-HO₂CC₆H₄C₆H₄CONHC₆H₄NH₂, starts

to decompose 123°. From EtOH it seps. with 1 mol. of EtOH of crystallization

Heated at 150°, H₂O is evolved and a 70% yield of

2',1-[o-benzoylene]-2-phenylbenzimidazole (IV), m. 177-8° results,

also formed in about the same yield by heating the components at

150°. Unlike the 6-membered ring of III, this compound yields

2'-[benzimidazolyl-2'']-diphenyl-2-carboxylic acid, m. 206-9°. Ag


salt. Et ester, m. 143° (decomposition). Amide, decomp. 227°.

Anilide, decomp. 248°. N-β-Phenylhydrazide, decomp.

157°. A by-product in the production of IV is N-[2''-

acetaminophenyl]diphenimide, decomp. 233°, which also results by

heating the anilide with AcCl . It is probably $(\text{C}_6\text{H}_4\text{CO})_2\text{NC}_6\text{H}_4\text{NHAc}$.
IT 861783-93-9P, 2-Benzimidazoleacrylanilide, α,β -diphenyl-
RL: PREP (Preparation)
(preparation of)
RN 861783-93-9 CAPLUS
CN Benzeneacetamide, α -(1H-benzimidazol-2-ylphenylmethylene)-N-phenyl-
(CA INDEX NAME)



=>